Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Mallinckrodt
Dow
Baxter
Medtronic

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR NUVARING


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Nuvaring

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00269620 ↗ PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra Completed Magee-Womens Hospital Phase 4 2005-06-01 This is an open-label prospective, multicenter, randomized trial to compare continuation rates into the fourth cycle of women using either the NuvaRing or OrthoEvra. Five hundred women will be recruited at 9 centers nationwide to be randomly assigned to use either the NuvaRing or OrthoEvra for four months. Women must either be on the pill or have recently stopped the pill and be relatively satisfied with oral contraceptive use to qualify for enrollment. Two visits and two phone calls will be required.
NCT00269620 ↗ PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra Completed Organon Phase 4 2005-06-01 This is an open-label prospective, multicenter, randomized trial to compare continuation rates into the fourth cycle of women using either the NuvaRing or OrthoEvra. Five hundred women will be recruited at 9 centers nationwide to be randomly assigned to use either the NuvaRing or OrthoEvra for four months. Women must either be on the pill or have recently stopped the pill and be relatively satisfied with oral contraceptive use to qualify for enrollment. Two visits and two phone calls will be required.
NCT00269620 ↗ PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra Completed University of Pittsburgh Phase 4 2005-06-01 This is an open-label prospective, multicenter, randomized trial to compare continuation rates into the fourth cycle of women using either the NuvaRing or OrthoEvra. Five hundred women will be recruited at 9 centers nationwide to be randomly assigned to use either the NuvaRing or OrthoEvra for four months. Women must either be on the pill or have recently stopped the pill and be relatively satisfied with oral contraceptive use to qualify for enrollment. Two visits and two phone calls will be required.
NCT00357526 ↗ Oral Contraceptive Pills Compared to Vaginal Rings Completed Organon N/A 2003-04-01 The purpose of this study is to determine whether teens and young women would prefer the Nuvaring to oral contraceptive pills after having tried both methods.
NCT00357526 ↗ Oral Contraceptive Pills Compared to Vaginal Rings Completed University of California, San Francisco N/A 2003-04-01 The purpose of this study is to determine whether teens and young women would prefer the Nuvaring to oral contraceptive pills after having tried both methods.
NCT00369967 ↗ Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents Terminated American College of Obstetricians and Gynecologists N/A 2007-02-01 We hypothesize that using "quick start" initiation of the contraceptive vaginal ring in adolescents seeking birth control will improve compliance compared to traditional start. We will conduct a randomized controlled trial comparing "quick start" to traditional start initiation of the contraceptive vaginal ring in adolescents seeking birth control. The primary study outcome is method continuation at 3, 6, and 12 months. Secondary outcomes include abnormal bleeding, product satisfaction, and adverse events.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nuvaring

Condition Name

Condition Name for Nuvaring
Intervention Trials
Contraception 6
Infertility 2
HIV 2
Bacterial Vaginosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nuvaring
Intervention Trials
Vaginosis, Bacterial 3
Polycystic Ovary Syndrome 2
Vaginal Diseases 2
Infertility 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nuvaring

Trials by Country

Trials by Country for Nuvaring
Location Trials
United States 28
Peru 2
South Africa 2
Finland 2
India 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nuvaring
Location Trials
Virginia 3
Illinois 3
California 3
New York 3
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nuvaring

Clinical Trial Phase

Clinical Trial Phase for Nuvaring
Clinical Trial Phase Trials
Phase 4 11
Phase 3 2
Phase 2 3
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nuvaring
Clinical Trial Phase Trials
Completed 17
Unknown status 4
Terminated 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nuvaring

Sponsor Name

Sponsor Name for Nuvaring
Sponsor Trials
Merck Sharp & Dohme Corp. 8
Organon 4
National Institute of Allergy and Infectious Diseases (NIAID) 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nuvaring
Sponsor Trials
Other 26
Industry 17
NIH 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Merck
Boehringer Ingelheim
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.